GENERAL ASSEMBLY OF NORTH CAROLINA SESSION 2021

FILED SENATE
May 25, 2022
S.B. 796
PRINCIPAL CLERK
D

 \mathbf{S}

SENATE BILL DRS45518-NBa-181

Short Title:	Sacred Relationship/Doctor/Patient.	(Public)
Sponsors:	Senator Hise (Primary Sponsor).	
Referred to:		
	A BILL TO BE ENTITLED	
AN ACT TO	PROTECT THE SACRED RELATIONSHIP OF PATIENT A	ND PHYSICIAN,
PHYSICI	IAN ASSISTANT, AND NURSE PRACTITIONER.	
The General	Assembly of North Carolina enacts:	
SI	ECTION 1. Article 1 of Chapter 90 of the General Statutes is an	mended by adding
a new section		
	Limited prescription, treatment, and administration prote	ction for certain
	ealth care professionals.	
	he North Carolina Medical Board and the North Carolina Board of	_
	to renew, suspend, or take any other disciplinary action again	
	practice medicine under this Article, (ii) a physician assistan	
	or (iii) a nurse practitioner licensed under G.S. 90-18.2 f	
	g a medication or supplement, including any of the drugs listed	
	n, physician assistant, or nurse practitioner believes is medically	
	COVID-19 to a patient for at-home use or for use in a health carbin spatian, the term "COVID-10" means the disease around by	
virus.	his section, the term "COVID-19" means the disease caused by	the SARS-COV-2
<u>virus.</u> (1) Ascorbic Acid.	
<u>(2</u>		
<u>(3</u>		
<u>(4</u>		
<u>(5</u>		
<u>(6</u>		
<u>(7</u>		
(8		
<u>(9</u>	Dutasteride.	
<u>(1</u>	0) Famotidine.	
<u>(1</u>	1) Flutamide.	
<u>(1</u>	2) <u>Fluvoxamine.</u>	
<u>(1</u>	3) <u>Heparin.</u>	
	4) <u>Hydroxychloroquine.</u>	
	<u>5)</u> <u>Ivermectin.</u>	
	6) Melatonin.	
	7) <u>Methylprednisolone.</u>	
	8) N-Acetyl-L-Cysteine.	
<u>(1</u>	9) Naltrexone.	



- 1 (20) Nitazoxanide.
 2 (21) Prednisone.
 3 (22) Spironolactone.
 4 (23) Thiamine.
 5 (24) Vitamin D.
 - (25) Zinc.

- (b) The North Carolina Medical Board and the North Carolina Board of Nursing shall not revoke, fail to renew, suspend, or take any other disciplinary action against (i) a physician licensed to practice medicine under this Article, (ii) a physician assistant licensed under G.S. 90-18.1, or (iii) a nurse practitioner licensed under G.S. 90-18.2 for doing any of the following actions:
 - (1) Providing a medical exemption to a patient who is unable to wear a protective mask, undergo a COVID-19 test, or receive a vaccination for COVID-19.
 - (2) Treating a patient who is unable to wear a protective mask, undergo a COVID-19 test, or receive a vaccination for COVID-19 for religious, medical, or philosophical reasons.
 - (3) Documenting a COVID-19 vaccine injury.
- (c) A physician acting in good faith in accordance with this section shall not solely constitute immoral or dishonorable conduct, as defined in G.S. 90-14(a)(1), or unprofessional conduct, as defined in G.S. 90-14(a)(6).
- (d) Nothing in this section shall be construed to grant greater liability protection to a physician's actions in accordance with this section than provided in Article 1B of this Chapter or other applicable provisions of law in this State.
- (e) If the North Carolina Medical Board or the North Carolina Board of Nursing violates this section, the physician, physician assistant, or nurse practitioner against whom the violation occurred may contest the case under all available administrative remedies available to the aggrieved party. For each separate violation of this section, the Board may be assessed a civil penalty not to exceed five hundred dollars (\$500.00). The clear proceeds of any civil penalty assessed under this section shall be remitted to the Civil Penalty and Forfeiture Fund in accordance with G.S. 115C-457.2."

SECTION 2. Article 4A of Chapter 90 of the General Statutes is amended by adding a new section to read:

"§ 90-85.15C. Limited protection for dispensing certain medications.

- (a) The North Carolina Board of Pharmacy shall not revoke, fail to renew, suspend, or take any other disciplinary action against a pharmacist for dispensing or administering a medication or supplement, including any of the drugs listed in this subsection, for the treatment of COVID-19 to a patient for at-home use or for use in a health care facility. For the purposes of this section, the term "COVID-19" means the disease caused by the SARS-CoV-2 virus.
 - (1) Ascorbic Acid.
 - (2) Aspirin.
 - (3) Atorvastatin.
 - (4) Azithromycin.
 - (5) <u>Budesonide.</u>
 - (6) Chloroquine.
 - (7) Colchicine.
 - (8) Cyproheptadine.
 - (9) Dutasteride.
 - (10) Famotidine.
 - (11) Flutamide.
 - (12) Fluvoxamine.
- 51 (13) Heparin.

Page 2 DRS45518-NBa-181

	General Assem	General Assembly Of North Carolina Session 202	
1	<u>(14)</u>	Hydroxychloroquine.	
2	<u>(15)</u>	<u>Ivermectin.</u>	
3	<u>(16)</u>	Melatonin.	
4	(17)	Methylprednisolone.	
5	(18)	N-Acetyl-L-Cysteine.	
6	$\overline{(19)}$	Naltrexone.	
7	(20)	Nitazoxanide.	
8	$\overline{(21)}$	Prednisone.	
9	$\overline{(22)}$	Spironolactone.	
10	$\overline{(23)}$	Thiamine.	
11	(24)	Vitamin D.	
12	$\overline{(25)}$	Zinc.	
13		e North Carolina Board of Pharmacy violates this section, the licensee against	
14	whom the viola	tion occurred may contest the case under all available administrative remedies	

(b) If the North Carolina Board of Pharmacy violates this section, the licensee against whom the violation occurred may contest the case under all available administrative remedies available to the aggrieved party. For each separate violation of this section, the Board may be assessed a civil penalty not to exceed five hundred dollars (\$500.00). The clear proceeds of any civil penalty assessed under this section shall be remitted to the Civil Penalty and Forfeiture Fund in accordance with G.S. 115C-457.2."

SECTION 3. The North Carolina Medical Board, the North Carolina Board of Nursing, and the North Carolina Board of Pharmacy shall adopt temporary rules to implement the provisions of this act.

SECTION 4. There is appropriated from the General Fund to the Department of Health and Human Services the nonrecurring sum of ten thousand dollars (\$10,000) for the 2022-2023 fiscal year to monitor the compliance of the North Carolina Medical Board, the North Carolina Board of Nursing, and the North Carolina Board of Pharmacy with the provisions of this act.

SECTION 5. Section 4 of this act becomes effective July 1, 2022. The remainder of this act becomes effective October 1, 2022, and applies to acts or omissions on or after that date.

DRS45518-NBa-181 Page 3